

## Article

# Synergism Potentiates Oxidative Antiproliferative Effects of Naringenin and Quercetin in MCF-7 Breast Cancer Cells

Mahasin Abdel Rhman, Nikita Devnarain, Rene Khan and Peter MO Owira \*

Molecular and Clinical Pharmacology Research Laboratory, Department of Pharmacology, Discipline of Pharmaceutical Sciences, University of Kwazulu-Natal, P.O. Box X5401, Durban 4000, South Africa

\* Correspondence: owirap@ukzn.ac.za; Tel.: +27-31-260-7720; Fax: +27-31-260-7907

**Abstract:** Breast cancer (BC) is the most frequently diagnosed type of cancer as of 2020. Quercetin (Que) and Naringenin (Nar) are predominantly found in citrus fruits and vegetables and have shown promising antiproliferative effects in multiple studies. It is also known that the bioactive effects of these flavonoids are more pronounced in whole fruit than in isolation. This study investigates the potential synergistic effects of Que and Nar (CoQN) in MCF-7 BC cells. MCF-7 cells were treated with a range of concentrations of Que, Nar or CoQN to determine cell viability. The IC<sub>50</sub> of CoQN was then used to investigate caspase 3/7 activity, Bcl-2 gene expression, lipid peroxidation and mitochondrial membrane potential to evaluate oxidative stress and apoptosis. CoQN treatment produced significant cytotoxicity, reduced Bcl-2 gene expression and increased caspase 3/7 activity compared to either Nar or Que. Furthermore, CoQN significantly increased lipid peroxidation and reduced mitochondrial membrane potential (MMP) compared to either Nar or Que. Therefore, CoQN treatment has potential pharmacological application in BC chemotherapy by inducing oxidative stress and apoptosis in MCF-7 BC cells. The results of this study support the increased consumption of whole fruits and vegetables to reduce cell proliferation in cancer.

**Keywords:** quercetin; naringenin; breast cancer; oxidative stress; apoptosis

**Citation:** Rhman, M.A.; Devnarain, N.; Khan, R.; Owira, P.M. Synergism Potentiates Oxidative Antiproliferative Effects of Naringenin and Quercetin in MCF-7 Breast Cancer Cells. *Nutrients* **2022**, *14*, 3437. <https://doi.org/10.3390/nu14163437>

Academic Editor: Francesca Oppedisano

Received: 21 July 2022

Accepted: 18 August 2022

Published: 21 August 2022

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).


## 1. Introduction

By 2020, breast cancer (BC) was the most frequently diagnosed type of cancer and the fifth leading cause of cancer-related deaths globally in women [1]. Despite technological advancements in the diagnosis and treatment, BC continues to burden the healthcare systems due to increased prevalence associated with socioeconomic disadvantages and continued exposure to risk factors [2]. BC mainly originates in the lobules or ducts of the breast and can be non-invasive or invasive, spreading to the lymph nodes and metastasizing to other parts of the body [3]. Its treatment requires a multidisciplinary approach involving surgery, radiation, chemotherapy, endocrine therapy and human epidermal growth factor receptor 2 (HER2)-targeted therapy depending on staging and molecular subtype [4]. Despite advancements in therapeutic approaches to BC, drug side effects due to narrow therapeutic indices and radiation burden reduce compliance. Therefore, novel therapeutic agents targeting BC cells with less cytotoxicity are required.

Polyphenolic flavonoids are plant-derived bioactive chemical substances [5] with anticancer, antioxidant, anti-inflammatory, antidiabetic and cardioprotective properties [6]. Flavonoids have been shown to exert their chemotherapeutic effects in various cancers by multiple pathways, including increased oxidative stress and apoptosis leading to reduced cell proliferation, invasion and migration [7]. Quercetin (Que) and Naringenin (Nar) are significant flavonoids found in many plant sources, including onions, broccoli, berries and citrus fruits [8,9]. Nar is the aglycone form of the flavanone glycoside, naringin

[9]. The pharmacological effects of Que or Nar have previously been investigated in vitro in MCF-7 and MDA-MB-231 cell lines and in vivo using xenografted or genetically modified BC mice models with promising results [10–12]. However, the administration of flavonoids usually requires high concentrations to produce a cytotoxic effect in cancer cells due to their low efficacy [13]. Co-administered flavonoids could have synergistic effects at lower concentrations and enhance selective toxicity in cancer cells [14–16]. We posit that plant bioactive chemical ingredients are more effective in their natural composition than when isolated. Compounds which are constituents of a particular plant can influence biological processes in a synergistic manner.

The intrinsic pathway of apoptosis (programmed cell death) involves non-receptor mediated intracellular signaling generated upon stimuli. In contrast, the extrinsic pathway requires binding an extracellular ligand to death receptors anchored in the cellular membrane [17]. Anti-apoptotic protein, Bcl-2, plays an essential role in preventing intrinsic pathway-induced apoptosis by inhibiting caspase cascade activation [18]. Bcl-2 protein expression is usually upregulated in cancerous cells resulting in increased proliferation and reduced apoptosis [19]. Flavonoids have been reported to exert their antiproliferative effects by downregulation of Bcl-2. This leads to the activation of the proapoptotic proteins of the Bcl-2 family, Bax and Bak, allowing their aggregation in the mitochondrial membrane. Subsequently, cytochrome complex (cyt-c) is released from the mitochondrion into the cytoplasm, which activates the apoptotic peptidase activating factor (Apaf1) protein. This activates caspase 9, which initiates the caspase cascade via the intrinsic pathway, leading to the induction of apoptosis [20] (Figure 1).



**Figure 1.** Schematic illustration of the effect of increased ROS production on Bcl-2 protein, MMP, caspase activity and intrinsic apoptotic pathway activation. ROS = Reactive oxygen species; MMP = Mitochondrial membrane potential; cyt-c = Cytochrome c; Apaf1 = Apoptotic peptidase activating factor 1; ↑ = Overproduction; ↓ = Down regulation; + = Activation.

Reactive oxygen species (ROS) are harmful free radicals, including hydroxyl radicals ( $\bullet\text{OH}$ ) and superoxide radicals ( $\text{O}_2^{\bullet-}$ ), or aid in the formation of free radicals, such as

hydrogen peroxide ( $\text{H}_2\text{O}_2$ ) and singlet oxygen ( $^1\text{O}_2$ ). They are counteracted and neutralized by enzymatic or non-enzymatic antioxidants [21]. An imbalance between ROS production and antioxidant activity results in oxidative stress and damage to cellular components, such as lipid membranes and nuclear and mitochondrial DNA [22]. Flavonoids have been shown to exert pro-oxidant effects in various types of cancer cells by several mechanisms, including auto-oxidation generating free radicals, the depletion of antioxidant stores and the inhibition of enzymatic antioxidant activity [23]. Oxidative stress can also cause a reduction in mitochondrial membrane potential (MMP) due to mitochondrial membrane damage. This leads to mitochondrial dysfunction, reduced Bcl-2 activity and the release of cyt-c into the cytoplasm, which activates the caspase cascade through the intrinsic apoptotic pathway [24,25] (Figure 1). Therefore, increased lipid peroxidation and reduced MMP are valuable indicators of oxidative stress-mediated apoptosis.

Therefore, this study aimed to examine the synergistic effect of Que and Nar co-administration (CoQN) compared to either flavonoid alone in MCF-7 BC cell lines. Cell viability, lipid peroxidation, mitochondrial dysfunction and apoptosis of MCF-7 BC cells were used as efficacy indices.

## 2. Materials and Methods

### 2.1. Cell Culture

MCF-7 cell lines were purchased from Cellonex® (Johannesburg). Cell lines were grown to 80% confluency in Dulbecco's modified Eagles' medium (DMEM) supplemented with 10% (*v/v*) fetal bovine serum, 1% (*v/v*) penicillin-streptomycin antibiotics, 1% (*v/v*) L-glutamine and 1% (*v/v*) HEPES buffer in 25 cm<sup>2</sup> flasks. The cell cultures were maintained at 37 °C in a humidified 5% CO<sub>2</sub> incubator. The media was changed every 24 to 48 h. All the work was carried out under aseptic techniques and cell culture protocol.

### 2.2. Cell Treatments

Que was purchased from Sigma-Aldrich Pty Ltd. (Johannesburg, South Africa; Pcode: 1002181950; CAS number: 117-39-5; Lot ID: SLBM7336V). Nar was purchased from Sigma-Aldrich Pty Ltd. (Johannesburg, South Africa; Pcode: 1002456338; CAS number: 67604-48-2; Lot ID: MKBW8640V). Dimethyl sulfoxide (DMSO) was used to prepare 10 mg/mL stock concentrations of Que and Nar. The cells were then exposed to either Que or Nar only or combined at concentrations required for assays with a final DMSO concentration of less than 0.01%.

### 2.3. Cell Viability Assays

Methylthiazol tetrazolium bromide (MTT) assay was used to determine MCF-7 cell viability. MCF-7 cells ( $1.5 \times 10^4$ /well) were seeded in a 96-well plate and incubated for 24 h. Cells were then treated with serial (0–250 µg/mL) concentrations of Que or Nar or a combination at a concentration range of 0–50 µg/mL. Three ratios (50:50, 40:60, and 60:40 for Nar:Que) were used in the combination treatments to assess the most effective ratio. After 24 h of treatment, 20 µL of 5 mg/mL MTT solution and 100 µL of cell culture media were added to the cells and incubated for 4 h. Afterwards, the MTT solution was aspirated and 100 µL of DMSO was added to solubilize the formazan dye. A microplate reader was used to measure absorbance at 570 nm, and cell viability was calculated as a percentage compared to the control.

### 2.4. Apoptosis Detection

Caspase 3/7 fluorometric assay (Biocom®, Johannesburg, South Africa) was used to determine apoptosis induction. MCF-7 cells were seeded in a 96-well plate ( $1.0 \times 10^4$ /well) and incubated for 24 h. The cells were then treated with Que, Nar or both at a

concentration of 44.31 µg/mL for 24 h. The cells were then treated with 100 µL of caspase loading solution for caspase 3/7 detection and incubated for 1 h at room temperature. After that, fluorescence was measured using a microplate reader at an excitation/emission wavelength of 535/620 nm. Results were expressed as relative fluorescence units (RFU).

### 2.5. Real-Time qPCR Analysis

Real-Time qPCR was used to assess the expression of anti-apoptotic Bcl-2 mRNA. Total RNA was extracted from MCF-7 cells previously treated with Nar, Que or both at a concentration of 44.31 µg/mL, respectively, using Quick-RNA Miniprep Kit (Zymo Research Ltd., Johannesburg, South Africa) according to the manufacturer's instructions. Complementary DNA (cDNA) was synthesized from extracted RNA using the iScript cDNA synthesis kit (BioRad, Hercules, CA, USA). Real-Time qPCR was carried out for Bcl-2 with β-actin as an internal control using the following primers (Biotec®, Johannesburg, South Africa): Bcl-2 (F: 5'-GGTGGTGGAGGAAGTCTTCA-3'; R: 5'-ATGCCGGTTCAGGTACTCAG-3'), β-actin (F: 5'-GGAGATTACTGCCCTGGCTCCTA-3'; R: 5'-GACTCATCGTACTCCTGCTTGCTG-3').

RT-qPCR amplification and measurement were performed using SSo advanced SYBR Green Supermix (BioRad®, Hercules, CA, USA) on BioRad qPCR thermocycler in the following conditions: 30 s at 95 °C for polymerase activation followed by 40 cycles of 5 s at 95 °C for denaturation and 15 s at 55 °C for annealing and extension. Gene expression was then analyzed and normalized against the internal control. Results were displayed relative fold change compared to the control ( $2^{-\Delta\Delta Ct}$ ) [26].

### 2.6. Thiobarbituric Acid Reactive Substances Assay

Thiobarbituric acid reactive substances (TBARS) assay was used to determine lipid peroxidation. MCF-7 cells were treated with Nar, Que or both at a concentration of 44.31 µg/mL. After that, 2% H<sub>3</sub>PO<sub>4</sub> was added to cell suspension ( $2 \times 10^5$  cells) in respective treatment tubes, whereas 0.1 M malondialdehyde (MDA) was used as a positive control. After that, 7% H<sub>3</sub>PO<sub>4</sub> was then added, followed by 400 µL of 0.1 mM thiobarbituric acid (TBA)/Butylated hydroxytoluene. Subsequently, 1 M HCl was added, and the tubes were heated in a water bath for 15 min. Butanol (1.5 mL) was then added, after which the absorbance of the resultant supernatant was measured in a 96-well using a microplate reader at 532 nm and 600 nm. MDA concentrations were then calculated using the extinction coefficient of the MDA-TBA adduct ( $155 \text{ mM}^{-1} \text{ cm}^{-1}$ ).

### 2.7. Mitochondrial Depolarization Detection

MMP was determined using JC-10 fluorometric assay kit (Sigma-Aldrich Ltd., St. Louis, MO, USA) according to the manufacturer's instructions. MCF-7 cells were seeded in a 96-well plate ( $1.5 \times 10^4$ /well) in triplicates following treatment with Que, Nar or CoQN at 44.31 µg/mL, respectively, for 24 h. After that, 50 µL of JC-10 loading dye was added to each well and incubated for 30 min in the dark. Red and green fluorescence were then measured using a microplate reader at an excitation/emission wavelength of 540/590 and 490/525, respectively. The ratio of red to green fluorescence was calculated to determine the MMP. Results were expressed as a percentage of control of the red/green fluorescence ratio.

### 2.8. Statistical Analysis


Statistical analyses were carried out using GraphPad Prism version 9.4.1., GraphPad Software, San Diego, CA, USA. The concentration–response inhibition equation using non-linear regression was used to analyze the IC<sub>50</sub> in the MTT assay. Statistical significance was assessed by unpaired t-test with Welch's correction for 2 variable comparisons of each treatment (Que, Nar and CoQN) against the control in the results obtained from the caspase 3/7 assay, Real-Time qPCR, TBARS assay and mitochondrial

depolarization assay. Treatment samples (Que, Nar and CoQN) were used in triplicate and experiments were repeated three times for all assays performed. A  $p$  value of  $<0.05$  was considered to indicate statistical significance.

### 3. Results

#### 3.1. MCF-7 Cell Viability

The MTT assay was used to assess the toxicity of Nar, Que or CoQN to MCF-7 BC cells and to determine cellular metabolic activity indicated by mitochondrial dehydrogenase activity. The administration of Que or Nar at a concentration range of 0–250  $\mu\text{g/mL}$  resulted in decreased toxicity to MCF-7 cells compared to CoQN-treated cells. Neither Nar nor Que showed a dose-dependent response, with extrapolated  $\text{IC}_{50}$  values of 468  $\mu\text{g/mL}$  and 91.10  $\mu\text{g/mL}$ , respectively (Figure 2A). At the 60:40 (N:Q) combination ratio, the calculated  $\text{IC}_{50}$  (44.31  $\mu\text{g/mL}$ ) and dose-dependence were significantly superior to either 50:50 or 40:60 ratios, respectively (Figure 2B). Hence, the 60:40 combination ratio was used in subsequent experiments.




**Figure 2.** Dose-dependent MCF-7 cell viability as determined MTT assay after the cells were exposed to (A): different concentrations of Nar or Que, respectively, and (B): different combination ratios of Nar and Que, respectively.


#### 3.2. Apoptosis Induction

Caspase 3/7 fluorometric assay was used to compare treatment effects with 44.31  $\mu\text{g/mL}$  of Que, Nar or both (CoQN) on the apoptosis of MCF-7 BC cells. CoQN significantly ( $p = 0.0052$ ) increased executioner caspase 3/7 activity compared to control or either Nar or Que, signifying increased cell apoptosis (Figure 3).

The gene expression of Bcl-2 in MCF-7 cells was determined by qPCR following the RNA isolation and cDNA synthesis of all treatment groups to measure the apoptosis pathway. CoQN significantly ( $p < 0.05$ ) reduced the mRNA expression of the anti-apoptotic Bcl-2 gene compared to either control or Que alone, signifying the activation of the intrinsic apoptotic pathway (Figure 4). Bcl-2 gene expression in Nar-treated cells was similar to CoQN.



**Figure 3.** Caspase 3/7 fluorometric assay after MCF-7 BC cells were exposed to 44.31  $\mu\text{g/mL}$  of Nar, Que or both, respectively. \*  $p < 0.05$  relative to control. \*\*  $p < 0.01$  relative to control. RFU = Relative fluorescence units; Ex/Em = Excitation/Emission; BC = Breast cancer; Nar = Naringenin; Que = Quercetin. CoQN = Co-administration of quercetin and naringenin.




**Figure 4.** BCL-2 gene expression as determined by qRT-PCR after MCF-7 BC cells were exposed to 44.31  $\mu\text{g/mL}$  of Nar, Que or CoQN, respectively. \*  $p < 0.05$  relative to control. \*\*  $p < 0.01$  relative to control. BC = Breast cancer; Nar = Naringenin; Que = Quercetin. CoQN = Co-administration of quercetin and naringenin.

### 3.3. Lipid Peroxidation

The TBARS assay was used to assess ROS production by quantifying the end-product of lipid peroxidation, MDA, in MCF-7 cells following 24-hour treatment with 44.31  $\mu\text{g/mL}$  of Que, Nar or both (CoQN) relative to control. The CoQN treatment significantly ( $p = 0.024$ ) increased MDA concentrations compared to the control, Que or Nar, respectively (Figure 5). Treatments with Que or Nar did not show a significant increase in MDA concentration compared to the control (Figure 5).






**Figure 5.** Lipid peroxidation measured by MDA concentrations after MCF-7 BC cells were exposed to 44.31  $\mu\text{g/mL}$  of Nar, Que or CoQN, respectively. \*  $p < 0.05$  relative to control. MDA = Malondialdehyde; BC = Breast cancer; Nar = Naringenin; Que = Quercetin. CoQN = Co-administration of quercetin and naringenin.

### 3.4. Mitochondrial Depolarization

Mitochondrial depolarization in MCF-7 cells was determined by assessing the MMP using the JC-10 dye following treatment with 44.31  $\mu\text{g/mL}$  of Que, Nar or CoQN, respectively. Treatment with CoQN or Nar significantly ( $p < 0.05$ ) decreased MMP compared to controls and Que (Figure 6), suggesting mitochondrial depolarization leading to induction of apoptosis.



**Figure 6.** MMP measured by red/green fluorescence ratio after MCF-7 BC cells were exposed to 44.31  $\mu\text{g/mL}$  of Nar, Que or CoQN, respectively. \*  $p < 0.05$  relative to control. MMP = Mitochondrial membrane potential; BC = Breast cancer; Nar = Naringenin; Que = Quercetin. CoQN = Co-administration of quercetin and naringenin.

#### 4. Discussion

Despite advancements in cancer therapeutics, current chemotherapeutic agents are still undesirable due to cytotoxicity and low selective toxicity [27]. Therefore, novel approaches, including combination therapies for targeting cancerous cells with minimal side effects, are required.

Previous studies have reported that Nar or Que exert promising chemotherapeutic effects in MCF-7 BC cells by reducing cell viability and inducing apoptosis [28–31]. However, high concentrations were required to achieve a minimum inhibitory response. Moreover, both Que and Nar have poor water solubility, which could impact their bioavailability for cellular uptake and further reduce efficacy [32,33]. In previous studies, a high concentration of 780–880  $\mu\text{M}$  (212–239  $\mu\text{g/mL}$ ) of Nar was needed to reduce cell viability by 50% ( $\text{IC}_{50}$ ) in MCF-7 BC cells [31]. This study used DMSO to dissolve Que and Nar to improve cellular uptake and penetration. An  $\text{IC}_{50}$  of 468  $\mu\text{g/mL}$  and 91.1  $\mu\text{g/mL}$  were determined for Nar and Que, respectively. However, our results showed that CoQN at a 60:40 ratio produced a significant synergistic effect on MCF-7 cell viability at a lower concentration (44.3  $\mu\text{g/mL}$ ) after a 24-hour incubation period compared to 40:60, 50:50 ratios and either flavonoid alone, respectively Figure 2A,B. This indicates the synergistic potency of the combination of the two flavonoids.

Chemotherapeutic cytotoxicity by increased apoptosis is an effective method in cancer treatment leading to the reduction of cell proliferation [19]. Caspases are cysteine proteases that play a vital role in apoptosis execution through intrinsic and extrinsic pathways. Caspase 3/7 are known as executioner caspases, whereas caspases 9 and 8 are responsible for caspase induction by the intrinsic and extrinsic apoptotic pathways [34]. Previous studies have reported apoptosis induction by caspase activation following treatment with Nar or Que in different cancers, including BC [11,35–39]. To evaluate the synergistic effects of CoQN on apoptosis induction in MCF-7, the level of caspase 3/7 activity was compared to either Que or Nar alone. Our findings demonstrated an increase in caspase 3/7 activity in MCF-7 after a 24-hour treatment period with Nar and Que alone compared to untreated cells (Figure 3). However, CoQN produced significantly higher caspase 3/7 activation compared to either Que or Nar alone at the same concentration (44.3  $\mu\text{g/mL}$ ), leading to more profound apoptosis induction and reduced cell proliferation (Figure 3).

Furthermore, the anti-apoptotic Bcl-2 protein activity was investigated by measuring its mRNA expression in the different treatment groups. The downregulation of Bcl-2 is a valuable mechanism for apoptosis induction via the intrinsic pathway [18,34]. Que and Nar have previously been reported to exert cytotoxic effects by regulating several members of the Bcl-2 family of proteins, including Bax, Bcl-xl and Bcl-2, resulting in intrinsic pathway-mediated apoptosis in neoplastic cells [40–47]. Our study shows that Que and Nar cause a significant decrease in Bcl-2 mRNA expression in MCF-7 cells compared to untreated cells (Figure 4). However, our study also showed that Nar or CoQN produced the significant downregulation of Bcl-2 expression compared to either Que or controls, suggesting a synergistic effect leading to intrinsic pathway-mediated apoptosis in MCF-7 BC cells (Figure 4).

The overproduction of intracellular ROS by endogenous or exogenous sources is one of the major driving forces leading to apoptosis induction [48]. ROS are mainly produced in mitochondria as metabolic by-products in biological systems [48]. Enzymatic antioxidants, such as catalase and superoxide dismutase (SOD), break down and remove free radicals. In contrast, non-enzymatic antioxidants, such as carotenoids and glutathione, convert free radicals into hydrogen peroxide ( $\text{H}_2\text{O}_2$ ) and then water, in the presence of metal cation cofactors [21]. Malignant cells lack some antioxidants, such as catalase, which is present in non-cancerous cells and cannot, therefore, neutralize free radicals.

Furthermore, flavonoids have been shown to exhibit pro-oxidant effects in cancer cells [49]. Some flavonoids can complex with metal cations, leading to the increased



production of superoxide ions through Fenton reactions, which induces apoptosis and halts cell proliferation [23]. Quercetin can also undergo auto-oxidation resulting in the formation of the radical, Quercetin-O•, which further leads to free radical accumulation [50] or can diminish glutathione stores and inhibit the enzymatic antioxidant, thioredoxin reductase [51,52]. Naringenin has also displayed pro-oxidant effects in malignant cells by inhibiting glutathione peroxidase and the ROS-dependent activation of ERK1/2 [53,54]. The overall increase in ROS production induces lipid peroxidation and MDA formation, which damages cellular components, such as membrane lipids, and mitochondrial DNA, leading to apoptosis and reduced cell proliferation [55].

The resultant oxidative stress-induced apoptosis has been reported in several neoplastic cells, including BC, hepatocellular carcinoma, cervical cancer and skin cancer [12,56–59]. In our study, neither Que nor Nar at a lower concentration (44.3 µg/mL) showed a significant increase in MDA production, indicating no significant increase in lipid peroxidation and ROS production. However, CoQN administration at the same concentration showed a significant increase in lipid peroxidation, signifying a synergistic effect resulting in increased ROS production (Figure 5). This agrees with a recent study which reported that high ROS production with Que leads to synergistic chemotherapeutic effects with tamoxifen in MCF-7 cells [56]. Nar and curcumin co-delivery in nanoparticles in MCF-7 cells also increased ROS production and apoptosis induction [60]. Furthermore, increased ROS production and lipid peroxidation has previously been linked to the downregulation of Bcl-2 expression associated with subsequent caspase 3/7 activation leading to apoptosis [61–63]. This can be connected to the observed significant reduction in Bcl-2 expression and increased caspase 3/7 activity observed with CoQN treatment (Figures 3 and 4).

Another marker of potential apoptosis induction is MMP reduction, indicating mitochondrial depolarization [64]. Excess intracellular ROS production is one of the major factors leading to mitochondrial dysfunction and associated decrease in MMP [65]. Antineoplastic effects of flavonoids have previously been reported [58,59,66–68]. Therefore, MMP expression was assessed in MCF-7 cells following Que, Nar or CoQN exposure. Results showed that CoQN caused a slightly significant decrease in MMP compared to either Que or Nar, respectively (Figure 6). The synergistic activity of Que with curcumin has previously been reported in a study by Zhang et al. in gastric cell lines, demonstrating a reduction in MMP with subsequent apoptosis induction and reduced cell proliferation [69]. Similarly, Nar and curcumin caused oxidative stress-induced mitochondrial depolarization resulting in apoptosis induction in MCF-7 cells [60]. Therefore, we propose that the observed reduction in MMP following CoQN exposure results from the synergistic pro-oxidant effects of Que and Nar in MCF-7 cells indicated by the significant increase in ROS production. We used 60:40 ratio for Que:Nar, which closely mirrors their relative native concentration ratios in citrus fruits [70] and the enhanced antiproliferative effects could be a manifestation of their biological effects in the native fruit. This approach would give an opportunity for formulation of these flavonoids or their synthetic analogs into effective biopharmaceuticals.

Therefore, it can be concluded that CoQN shows promising synergistic antiproliferative effects in MCF-7 cells compared to either Nar or Que, respectively; by increasing lipid peroxidation, inducing mitochondrial depolarization, anti-apoptotic Bcl-2 suppression and concomitant activation of caspase 3/7. Flavonoids are known to be non-toxic to non-malignant cells [11,71,72]; hence more studies are suggested to confirm their antineoplastic role in this regard.

## 5. Conclusions

The co-administration of the flavonoids Que and Nar shows promising synergistic antiproliferative effects in MCF-7 BC cells compared to either alone by significantly increasing oxidative stress, reducing MMP and inducing apoptosis, leading to cytotoxicity and a reduction in cell viability. Our results here support the notion that the increased

consumption of fruits and vegetables rich in these flavonoids is associated with a reduced incidence of many types of cancers. We posit that these flavonoid combinations further be developed as chemotherapeutic agents against breast cancer. These flavonoids or their synthetic analogs could further be investigated and delivered in vivo via appropriate vehicles in nanoparticles delivery system as biopharmaceuticals.

**Author Contributions:** M.A.R. Conceptualization, Methodology, Investigation, Writing—Original draft; N.D.: Conceptualization, Methodology, Investigation; R.K.: Investigation; P.M.O.: Conceptualization, Supervision, Writing—Review and Editing. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Acknowledgments:** We acknowledge our research team at the Molecular and Clinical Pharmacology Research Laboratory for the thought-provoking discussions on this subject. We are also indebted to the Research Office of the University of KwaZulu-Natal for financial assistance via productivity awards to complete this work.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J. Clin.* **2021**, *71*, 209–249. <https://doi.org/10.3322/caac.21660>.
2. Omran, A.R. The epidemiologic transition: A theory of the epidemiology of population change. *Milbank Q.* **2005**, *83*, 731–757. <https://doi.org/10.1111/j.1468-0009.2005.00398.x>.
3. Watkins, E.J. Overview of breast cancer. *J. Am. Acad. Physician Assist.* **2019**, *32*, 13–17. <https://doi.org/10.1097/01.JAA.0000580524.95733.3d>.
4. Maughan, K.L.; Lutterbie, M.A.; Ham, P.S. Treatment of breast cancer. *Am. Fam. Physician* **2010**, *81*, 1339–1346.
5. Ververidis, F.; Trantas, E.; Douglas, C.; Vollmer, G.; Kretschmar, G.; Panopoulos, N. Biotechnology of flavonoids and other phenylpropanoid-derived natural products. Part I: Chemical diversity, impacts on plant biology and human health. *Biotechnol. J.* **2007**, *2*, 1214–1234. <https://doi.org/10.1002/biot.200700084>.
6. Kumar, S.; Pandey, A.K. Chemistry and biological activities of flavonoids: An overview. *Sci. World J.* **2013**, *2013*, 162750. <https://doi.org/10.1155/2013/162750>.
7. Amawi, H.; Ashby, C.R.; Tiwari, A.K. Cancer chemoprevention through dietary flavonoids: What's limiting? *Chin. J. Cancer* **2017**, *36*, 50. <https://doi.org/10.1186/s40880-017-0217-4>.
8. Andres, S.; Pevny, S.; Ziegenhagen, R.; Bakhiya, N.; Schäfer, B.; Hirsch-Ernst, K.I.; Lampen, A. Safety aspects of the use of quercetin as a dietary supplement. *Mol. Nutr. Food Res.* **2018**, *62*, 1700447. <https://doi.org/10.1002/mnfr.201700447>.
9. Salehi, B.; Fokou, P.V.T.; Sharifi-Rad, M.; Zucca, P.; Pezzani, R.; Martins, N.; Sharifi-Rad, J. The Therapeutic Potential of Naringenin: A Review of Clinical Trials. *Pharmaceuticals* **2019**, *12*, 11. <https://doi.org/10.3390/ph12010011>.
10. Ezzati, M.; Yousefi, B.; Velaei, K.; Safa, A. A review on anticancer properties of quercetin in breast cancer. *Life Sci.* **2020**, *248*, 117463. <https://doi.org/10.1016/j.lfs.2020.117463>.
11. Zhao, Z.; Jin, G.; Ge, Y.; Guo, Z. Naringenin inhibits migration of breast cancer cells via inflammatory and apoptosis cell signaling pathways. *Inflammopharmacology* **2019**, *27*, 1021–1036. <https://doi.org/10.1007/s10787-018-00556-3>.
12. Rajamani, S.; Radhakrishnan, A.; Sengodan, T.; Thangavelu, S. Augmented anticancer activity of naringenin-loaded TPGS polymeric nanosuspension for drug resistive MCF-7 human breast cancer cells. *Drug Dev. Ind. Pharm.* **2018**, *44*, 1751–1761. <https://doi.org/10.1080/03639045.2018.1496445>.
13. Kale, A.; Gawande, S.; Kotwal, S. Cancer phytotherapeutics: Role for flavonoids at the cellular level. *Phytother. Res.* **2008**, *22*, 567–577. <https://doi.org/10.1002/ptr.2283>.
14. Campbell, J.K.; King, J.L.; Harmston, M.; Lila, M.A.; Erdman, J.W., Jr. Synergistic effects of flavonoids on cell proliferation in Hepa-1c1c7 and LNCaP cancer cell lines. *J. Food Sci.* **2006**, *71*, S358–S363. <https://doi.org/10.1111/j.1750-3841.2006.00013.x>.
15. Yang, C.; Gundala, S.R.; Mukkavilli, R.; Vangala, S.; Reid, M.D.; Aneja, R. Synergistic interactions among flavonoids and acetogenins in *Graviola* (*Annona muricata*) leaves confer protection against prostate cancer. *Carcinogenesis* **2015**, *36*, 656–665. <https://doi.org/10.1093/carcin/bgv046>.

16. Ackland, M.L.; van de Waarsenburg, S.; Jones, R. Synergistic antiproliferative action of the flavonols quercetin and kaempferol in cultured human cancer cell lines. *Vivo* **2005**, *19*, 69–76.
17. Xu, X.; Lai, Y.; Hua, Z.C. Apoptosis and apoptotic body: Disease message and therapeutic target potentials. *Biosci. Rep.* **2019**, *39*, BSR20180992. <https://doi.org/10.1042/bsr20180992>.
18. Bruckheimer, E.M.; Cho, S.H.; Sarkiss, M.; Herrmann, J.; McDonnell, T.J. The Bcl-2 gene family and apoptosis. *Adv. Biochem. Eng. Biotechnol.* **1998**, *62*, 75–105. <https://doi.org/10.1007/BFb0102306>.
19. Makin, G.; Hickman, J.A. Apoptosis and cancer chemotherapy. *Cell Tissue Res.* **2000**, *301*, 143–152. <https://doi.org/10.1007/s004419900160>.
20. Ramos, S. Effects of dietary flavonoids on apoptotic pathways related to cancer chemoprevention. *J. Nutr. Biochem.* **2007**, *18*, 427–442. <https://doi.org/10.1016/j.jnutbio.2006.11.004>.
21. Nimse, S.B.; Pal, D. Free radicals, natural antioxidants, and their reaction mechanisms. *RSC Adv.* **2015**, *5*, 27986–28006. <https://doi.org/10.1039/C4RA13315C>.
22. Klaunig, J.E. Oxidative Stress and Cancer. *Curr. Pharm. Des.* **2018**, *24*, 4771–4778. <https://doi.org/10.2174/138161282566190215121712>.
23. Slika, H.; Mansour, H.; Wehbe, N.; Nasser, S.A.; Iratni, R.; Nasrallah, G.; Shaito, A.; Ghaddar, T.; Kobeissy, F.; Eid, A.H. Therapeutic potential of flavonoids in cancer: ROS-mediated mechanisms. *Biomed. Pharmacother.* **2022**, *146*, 112442. <https://doi.org/10.1016/j.biopha.2021.112442>.
24. Ježek, J.; Cooper, K.F.; Strich, R. Reactive Oxygen Species and Mitochondrial Dynamics: The Yin and Yang of Mitochondrial Dysfunction and Cancer Progression. *Antioxidants* **2018**, *7*, 13. <https://doi.org/10.3390/antiox7010013>.
25. Um, H.D. Bcl-2 family proteins as regulators of cancer cell invasion and metastasis: A review focusing on mitochondrial respiration and reactive oxygen species. *Oncotarget* **2016**, *7*, 5193–5203. <https://doi.org/10.18632/oncotarget.6405>.
26. Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* **2001**, *25*, 402–408. <https://doi.org/10.1006/meth.2001.1262>.
27. Knezevic, C.E.; Clarke, W. Cancer Chemotherapy: The Case for Therapeutic Drug Monitoring. *Ther. Drug Monit.* **2020**, *42*, 6–19. <https://doi.org/10.1097/ftd.0000000000000701>.
28. Khorsandi, L.; Orazizadeh, M.; Niazvand, F.; Abbaspour, M.R.; Mansouri, E.; Khodadadi, A. Quercetin induces apoptosis and necroptosis in MCF-7 breast cancer cells. *Bratisl. Med. J.* **2017**, *118*, 123–128. [https://doi.org/10.4149/bll\\_2017\\_025](https://doi.org/10.4149/bll_2017_025).
29. Aghapour, F.; Moghadamnia, A.A.; Nicolini, A.; Kani, S.N.M.; Barari, L.; Morakabati, P.; Rezazadeh, L.; Kazemi, S. Quercetin conjugated with silica nanoparticles inhibits tumor growth in MCF-7 breast cancer cell lines. *Biochem. Biophys. Res. Commun.* **2018**, *500*, 860–865. <https://doi.org/https://doi.org/10.1016/j.bbrc.2018.04.174>.
30. Helle, J.; Kräker, K.; Bader, M.I.; Keiler, A.M.; Zierau, O.; Vollmer, G.; Welsh, J.; Kretzschmar, G. Assessment of the proliferative capacity of the flavanones 8-prenylnaringenin, 6-(1,1-dimethylallyl)naringenin and naringenin in MCF-7 cells and the rat mammary gland. *Mol. Cell. Endocrinol.* **2014**, *392*, 125–135. <https://doi.org/10.1016/j.mce.2014.05.014>.
31. Kocyigit, A.; Koyuncu, I.; Dikilitas, M.; Bahadori, F.; Turkkan, B. Cytotoxic, genotoxic and apoptotic effects of naringenin-oxime relative to naringenin on normal and cancer cell lines. *Asian Pac. J. Trop. Biomed.* **2016**, *6*, 872–880. <https://doi.org/10.1016/j.apjtb.2016.08.004>.
32. Batiha, G.E.-S.; Beshbishy, A.M.; Ikram, M.; Mulla, Z.S.; El-Hack, M.E.A.; Taha, A.E.; Algammal, A.M.; Elewa, Y.H.A. The Pharmacological Activity, Biochemical Properties, and Pharmacokinetics of the Major Natural Polyphenolic Flavonoid: Quercetin. *Foods* **2020**, *9*, 374. <https://doi.org/10.3390/foods9030374>.
33. Joshi, R.; Kulkarni, Y.A.; Wairkar, S. Pharmacokinetic, pharmacodynamic and formulations aspects of naringenin: An update. *Life Sci.* **2018**, *215*, 43–56. <https://doi.org/10.1016/j.lfs.2018.10.066>.
34. Fan, T.J.; Han, L.H.; Cong, R.S.; Liang, J. Caspase family proteases and apoptosis. *Acta Biochim. et Biophys. Sin.* **2005**, *37*, 719–727. <https://doi.org/10.1111/j.1745-7270.2005.00108.x>.
35. Shi, X.; Luo, X.; Chen, T.; Guo, W.; Liang, C.; Tang, S.; Mo, J. Naringenin inhibits migration, invasion, induces apoptosis in human lung cancer cells and arrests tumour progression in vitro. *J. Cell Mol. Med.* **2021**, *25*, 2563–2571. <https://doi.org/10.1111/jcmm.16226>.
36. Bao, L.; Liu, F.; Guo, H.-B.; Li, Y.; Tan, B.-B.; Zhang, W.-X.; Peng, Y.-H. naringenin inhibits proliferation, migration, and invasion as well as induces apoptosis of gastric cancer SGC7901 cell line by downregulation of AKT pathway. *Tumour Biol.* **2016**, *37*, 11365–11374. <https://doi.org/10.1007/s13277-016-5013-2>.
37. Chou, C.-C.; Yang, J.-S.; Lu, H.-F.; Ip, S.-W.; Lo, C.; Wu, C.-C.; Lin, J.-P.; Tang, N.-Y.; Chung, J.-G.; Chou, M.-J.; et al. Quercetin-mediated cell cycle arrest and apoptosis involving activation of a caspase cascade through the mitochondrial pathway in human breast cancer MCF-7 cells. *Arch. Pharmacol. Res.* **2010**, *33*, 1181–1191. <https://doi.org/10.1007/s12272-010-0808-y>.
38. Mutlu Altundag, E.; Kasaci, T.; Yilmaz, A.M.; Karademir, B.; Koçtürk, S.; Taga, Y.; Yalçın, A.S. Quercetin-Induced Cell Death in Human Papillary Thyroid Cancer (B-CPAP) Cells. *J. Thyroid Res.* **2016**, *2016*, 9843675. <https://doi.org/10.1155/2016/9843675>.
39. Sundaram, M.K.; Raina, R.; Afroze, N.; Bajbouj, K.; Hamad, M.; Haque, S.; Hussain, A. quercetin modulates signaling pathways and induces apoptosis in cervical cancer cells. *Biosci. Rep.* **2019**, *39*, BSR20190720. <https://doi.org/10.1042/bsr20190720>.
40. Lu, W.L.; Yu, C.R.; Lien, H.M.; Sheu, G.T.; Cherng, S.H. Cytotoxicity of naringenin induces Bax-mediated mitochondrial apoptosis in human lung adenocarcinoma A549 cells. *Environ. Toxicol.* **2020**, *35*, 1386–1394. <https://doi.org/10.1002/tox.23003>.
41. Lim, W.; Park, S.; Bazer, F.W.; Song, G. Naringenin-induced Apoptotic cell death in prostate cancer cells is mediated via the PI3K/AKT and MAPK signaling pathways. *J. Cell Biochem.* **2017**, *118*, 1118–1131. <https://doi.org/10.1002/jcb.25729>.

42. Jin, C.-Y.; Park, C.; Lee, J.-H.; Chung, K.T.; Kwon, T.K.; Kim, G.-Y.; Choi, B.T.; Choi, Y.H. Naringenin-induced apoptosis is attenuated by Bcl-2 but restored by the small molecule Bcl-2 inhibitor, HA 14-1, in human leukemia U937 cells. *Toxicol. Vitro* **2009**, *23*, 259–265. <https://doi.org/10.1016/j.tiv.2008.12.005>.
43. Noori, S.; Rezaei Tavirani, M.; Deravi, N.; Mahboobi Rabbani, M.I.; Zarghi, A. Naringenin enhances the anti-cancer effect of cyclophosphamide against MDA-MB-231 breast cancer cells via targeting the STAT3 signaling Ppathway. *Iran. J. Pharm. Res.* **2020**, *19*, 122–133. <https://doi.org/10.22037/ijpr.2020.113103.14112>.
44. Özsoy, S.; Becer, E.; Kabadayı, H.; Vatansever, H.S.; Yücecan, S. Quercetin-mediated apoptosis and cellular senescence in human colon cancer. *Anti-Cancer Agents Med. Chem.* **2020**, *20*, 1387–1396. <https://doi.org/10.2174/1871520620666200408082026>.
45. Teekaraman, D.; Elayapillai, S.P.; Viswanathan, M.P.; Jagadeesan, A. Quercetin inhibits human metastatic ovarian cancer cell growth and modulates components of the intrinsic apoptotic pathway in PA-1 cell line. *Chem. Biol. Interact.* **2019**, *300*, 91–100. <https://doi.org/10.1016/j.cbi.2019.01.008>.
46. Vijayababu, M.R.; Kanagaraj, P.; Arunkumar, A.; Ilangovan, R.; Dharmarajan, A.; Arunakaran, J. Quercetin induces p53-independent apoptosis in human prostate cancer cells by modulating Bcl-2-related proteins: A possible mediation by IGFBP-3. *Oncol. Res.* **2006**, *16*, 67–74. <https://doi.org/10.3727/000000006783981224>.
47. Duo, J.; Ying, G.G.; Wang, G.W.; Zhang, L. Quercetin inhibits human breast cancer cell proliferation and induces apoptosis via Bcl-2 and Bax regulation. *Mol Med Rep.* **2012**, *5*, 1453–1456. <https://doi.org/10.3892/mmr.2012.845>.
48. Pizzino, G.; Irrera, N.; Cucinotta, M.; Pallio, G.; Mannino, F.; Arcoraci, V.; Squadrito, F.; Altavilla, D.; Bitto, A. Oxidative stress: Harms and Bbenefits for human health. *Oxid. Med. Cell. Longev.* **2017**, *2017*, 8416763. <https://doi.org/10.1155/2017/8416763>.
49. León-González, A.J.; Auger, C.; Schini-Kerth, V.B. Pro-oxidant activity of polyphenols and its implication on cancer chemoprevention and chemotherapy. *Biochem. Pharmacol.* **2015**, *98*, 371–380. <https://doi.org/10.1016/j.bcp.2015.07.017>.
50. Jeong, J.H.; An, J.Y.; Kwon, Y.T.; Rhee, J.G.; Lee, Y.J. Effects of low dose quercetin: Cancer cell-specific inhibition of cell cycle progression. *J. Cell Biochem.* **2009**, *106*, 73–82. <https://doi.org/10.1002/jcb.21977>.
51. Gibellini, L.; Pinti, M.; Nasi, M.; De Biasi, S.; Roat, E.; Bertoncelli, L.; Cossarizza, A. Interfering with ROS metabolism in cancer cells: The potential role of quercetin. *Cancers* **2010**, *2*, 1288–1311. <https://doi.org/10.3390/cancers2021288>.
52. Lu, J.; Papp, L.V.; Fang, J.; Rodriguez-Nieto, S.; Zhivotovsky, B.; Holmgren, A. Inhibition of mammalian thioredoxin reductase by some flavonoids: Implications for myricetin and quercetin anticancer activity. *Cancer Res.* **2006**, *66*, 4410–4418. <https://doi.org/10.1158/0008-5472.Can-05-3310>.
53. Yen, G.C.; Duh, P.D.; Tsai, H.L.; Huang, S.L. Pro-oxidative properties of flavonoids in human lymphocytes. *Biosci. Biotechnol. Biochem.* **2003**, *67*, 1215–1222. <https://doi.org/10.1271/bbb.67.1215>.
54. Park, S.; Lim, W.; Bazer, F.W.; Song, G. Naringenin suppresses growth of human placental choriocarcinoma via reactive oxygen species-mediated P38 and JNK MAPK pathways. *Phytomedicine* **2018**, *50*, 238–246. <https://doi.org/10.1016/j.phymed.2017.08.026>.
55. Barrera, G. Oxidative stress and lipid peroxidation products in cancer progression and therapy. *ISRN Oncol.* **2012**, *2012*, 137289. <https://doi.org/10.5402/2012/137289>.
56. Xu, Z.; Zhao, D.; Zheng, X.; Huang, B.; Xia, X.; Pan, X. Quercetin exerts bidirectional regulation effects on the efficacy of tamoxifen in estrogen receptor-positive breast cancer therapy: An in vitro study. *Environ. Toxicol.* **2020**, *35*, 1179–1193. <https://doi.org/10.1002/tox.22983>.
57. Chang, Y.-F.; Chi, C.-W.; Wang, J.-J. Reactive Oxygen Species production is involved in quercetin-induced apoptosis in human hepatoma cells. *Nutr. Cancer* **2006**, *55*, 201–209. [https://doi.org/10.1207/s15327914nc5502\\_12](https://doi.org/10.1207/s15327914nc5502_12).
58. Bishayee, K.; Ghosh, S.; Mukherjee, A.; Sadhukhan, R.; Mondal, J.; Khuda-Bukhsh, A.R. Quercetin induces cytochrome-c release and ROS accumulation to promote apoptosis and arrest the cell cycle in G2/M, in cervical carcinoma: Signal cascade and drug-DNA interaction. *Cell Prolif.* **2013**, *46*, 153–163. <https://doi.org/10.1111/cpr.12017>.
59. Ahamad, M.S.; Siddiqui, S.; Jafri, A.; Ahmad, S.; Afzal, M.; Arshad, M. Induction of apoptosis and antiproliferative activity of naringenin in human epidermoid carcinoma cell through ROS generation and cell cycle arrest. *PLoS ONE* **2014**, *9*, e110003. <https://doi.org/10.1371/journal.pone.0110003>.
60. Askar, M.A.; El Shawi, O.E.; Abou Zaid, O.A.R.; Mansour, N.A.; Hanafy, A.M. Breast cancer suppression by curcumin-naringenin-magnetic-nano-particles: In vitro and in vivo studies. *Tumour Biol.* **2021**, *43*, 225–247. <https://doi.org/10.3233/tub-211506>.
61. Hildeman, D.A.; Mitchell, T.; Aronow, B.; Wojciechowski, S.; Kappler, J.; Marrack, P. Control of Bcl-2 expression by reactive oxygen species. *Proc. Natl. Acad. Sci. USA* **2003**, *100*, 15035–15040. <https://doi.org/10.1073/pnas.1936213100>.
62. Pugazhenth, S.; Nesterova, A.; Jambal, P.; Audesirk, G.; Kern, M.; Cabell, L.; Eves, E.; Rosner, M.R.; Boxer, L.M.; Reusch, J.E.-B. Oxidative stress-mediated down-regulation of bcl-2 promoter in hippocampal neurons. *J. Neurochem.* **2003**, *84*, 982–996. <https://doi.org/10.1046/j.1471-4159.2003.01606.x>.
63. Su, L.-J.; Zhang, J.-H.; Gomez, H.; Murugan, R.; Hong, X.; Xu, D.; Jiang, F.; Peng, Z.-Y. Reactive Oxygen Species-induced lipid peroxidation in apoptosis, autophagy, and ferroptosis. *Oxidative Med. Cell. Longev.* **2019**, *2019*, 5080843. <https://doi.org/10.1155/2019/5080843>.
64. Ly, J.D.; Grubb, D.R.; Lawen, A. The mitochondrial membrane potential ( $\Delta\psi_m$ ) in apoptosis; an update. *Apoptosis* **2003**, *8*, 115–128. <https://doi.org/10.1023/A:1022945107762>.
65. Kudryavtseva, A.V.; Krasnov, G.S.; Dmitriev, A.A.; Alekseev, B.Y.; Kardymon, O.L.; Sadritdinova, A.F.; Fedorova, M.S.; Pokrovsky, A.V.; Melnikova, N.V.; Kaprin, A.D.; et al. Mitochondrial dysfunction and oxidative stress in aging and cancer. *Oncotarget* **2016**, *7*, 44879–44905. <https://doi.org/10.18632/oncotarget.9821>.

66. Rajendran, P.; Maheshwari, U.; Muthukrishnan, A.; Muthuswamy, R.; Anand, K.; Ravindran, B.; Dhanaraj, P.; Balamuralikrishnan, B.; Chang, S.W.; Chung, W.J. Myricetin: Versatile plant based flavonoid for cancer treatment by inducing cell cycle arrest and ROS-reliant mitochondria-facilitated apoptosis in A549 lung cancer cells and in silico prediction. *Mol. Cell Biochem.* **2021**, *476*, 57–68. <https://doi.org/10.1007/s11010-020-03885-6>.
67. Kocyigit, A.; Guler, E.M. Curcumin induce DNA damage and apoptosis through generation of reactive oxygen species and reducing mitochondrial membrane potential in melanoma cancer cells. *Cell Mol. Biol.* **2017**, *63*, 97–105. <https://doi.org/10.14715/cmb/2017.63.11.17>.
68. Chen, Y.; Wang, S.; Geng, B.; Yi, Z. Pelargonidin induces antitumor effects in human osteosarcoma cells via autophagy induction, loss of mitochondrial membrane potential, G2/M cell cycle arrest and downregulation of PI3K/AKT signalling pathway. *J. BUON* **2018**, *23*, 735–740.
69. Zhang, J.-Y.; Lin, M.-T.; Zhou, M.-J.; Yi, T.; Tang, Y.-N.; Tang, S.-L.; Yang, Z.-J.; Zhao, Z.-Z.; Chen, H.-B. Combinational treatment of curcumin and quercetin against gastric cancer MGC-803 Cells in vitro. *Molecules* **2015**, *20*, 11524–11534. <https://doi.org/10.3390/molecules200611524>.
70. Ross, S.A.; Ziska, D.S.; Zhao, K.; Elsohly, M.A. Variance of common flavonoids by brand of grapefruit juice. *Fitoterapia* **2000**, *71*, 154–156. [https://doi.org/10.1016/s0367-326x\(99\)00131-8](https://doi.org/10.1016/s0367-326x(99)00131-8).
71. Niazvand, F.; Orazizadeh, M.; Khorsandi, L.; Abbaspour, M.; Mansouri, E.; Khodadadi, A. Effects of quercetin-loaded nanoparticles on MCF-7 human breast cancer cells. *Medicina* **2019**, *55*, 114. <https://doi.org/10.3390/medicina55040114>.
72. Khan, H.; Ullah, H.; Martorell, M.; Valdes, S.E.; Belwal, T.; Tejada, S.; Sureda, A.; Kamal, M.A. Flavonoids nanoparticles in cancer: Treatment, prevention and clinical prospects. *Semin. Cancer Biol.* **2021**, *69*, 200–211. <https://doi.org/https://doi.org/10.1016/j.semcancer.2019.07.023>.